Login to Your Account



Clinic Roundup


Monday, January 28, 2013
• Seattle Genetics Inc., of Bothell, Wash., said interim results from a Phase I trial of ASG-5ME in metastatic pancreatic ductal adenocarcinoma identified the maximum-tolerated dose for weekly administration, demonstrated tolerability and provided preliminary evidence for antitumor activity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription